As traditional treatments for cancer are being surpassed by immunotherapies, the way in which healthcare providers deliver services must change. Speaking from the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, Yvonne Summers, BSc, MB ChB, MSc, PhD, FRCP from The Christie NHS Foundation Trust, Manchester, UK, discusses the transformations facing multidisciplinary teams in dealing with the care of cancer patients receiving immunotherapy. Dr Summers highlights the vital role of the pharmacist in the adoption of novel immunotherapies, particularly in reference to toxicities and patient education.
The role of pharmacists in the adoption of novel cancer immunotherapies
